Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimber, A.
Right arrow Articles by Gespach, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimber, A.
Right arrow Articles by Gespach, C.
[Cancer Research 60, 672-678, February 1, 2000]
© 2000 American Association for Cancer Research

Experimental Therapeutics

Functional Interactions between Bile Acids, All-Trans Retinoic Acid, and 1,25-Dihydroxy-Vitamin D3 on Monocytic Differentiation and Myeloblastin Gene Down-Regulation in HL60 and THP-1 Human Leukemia Cells1

Amazia Zimber2, Annick Chedeville, Jean-Pierre Abita, Veronique Barbu and Christian Gespach

The Hebrew University of Jerusalem, Faculty of Agriculture, Department of Animal Science, Rehovot 76100, Israel [A. Z.]; Institut Universitaire d’Hématologie, Hôpital Saint-Louis, 75475 Paris cedex 10, France [A. C., J. P. A.]; INSERM Unité 402, Faculté de Médecine Saint-Antoine, Université Paris VI, 75571 Paris Cedex 12, France [V. B.]; and INSERM Unité 482, Hôpital Saint-Antoine, 75571 Paris cedex 12, France [A. Z., C. G.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Bile acids were shown previously to inhibit proliferation and to induce monocytic differentiation in HL60 human acute promyelocytic leukemia cells (A. Zimber et al., Int. J. Cancer, 59: 71–77, 1994). In this report, we hypothesized that bile acids may exert a positive cooperativity with two known inducers of leukemic cell differentiation, all-trans retinoic acid and 1,25(OH)2-vitamin D3. Our results provide evidence that bile acids induced the monocytic differentiation of HL60 and THP-1 human leukemia cells exposed to ineffective concentrations of these inducers. The protein kinase C (PKC) inhibitors H-7 (10 and 20 µM) and staurosporine (5 and 20 nM) modulated the effects of bile acids on HL60 cell differentiation. Most interestingly, bile acids are shown herein to down-regulate the expression of the serine protease myeloblastin gene involved in the differentiation of myeloid hematopoietic cells.

In agreement with the recent identification of nuclear receptors for bile acids, our data suggest that functional interactions between nuclear bile acid signaling pathways, PKC, and nuclear receptors for retinoic acid and vitamin D3 are involved in the down-regulation of the myeloblastin gene and the induction of cell differentiation in human leukemic cells.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Differentiation-inducing drugs are often used in combination with other compounds that either induce cellular differentiation or exert cytostatic or cytotoxic effects (1 , 2) . They may then act in an additive or even synergistic manner (3) . In such combination therapy, drugs are used simultaneously or sequentially, even at lower concentrations that are not effective or only slightly effective when administered alone, to obtain a significant therapeutic gain, e.g., inhibition of tumor cell proliferation and induction of differentiation. Practically, this means that side effects may be reduced considerably without losing the desired maximal therapeutic effect of the drugs (4) .

Previously, we have shown that several primary and secondary bile acids can inhibit the proliferation and induce maturation-differentiation in HL60 human acute promyelocytic leukemia cells in vitro (5) . Thus, after 3–5 days of treatment, these cells were engaged in the monocytic pathway of maturation and differentiation, as judged by morphological examination, NBT3 test, and binding of monoclonal antibodies specific for cell surface differentiation antigens. At the same time, cell cycle analysis showed a very significant accumulation of HL60 cells at the G0-G1 boundary, with a concomitant decrease in the percentage of cells at the S phase (5) .

Because the concentrations of bile acids we used to induce the differentiation of HL60 cells (50–100 µM) were similar to serum levels in patients with cholestasis of pregnancy or bile acid concentration in portal blood (6 , 7) , we decided to extend this study by testing the hypothesis that bile acids may cooperate with well-known natural inducers of differentiation in HL60 and THP-1 cells, along the monocytic or granulocytic pathways. For this purpose, we used ATRA and Vit D3 at different concentrations, including noneffective ones. Both inducers are physiological and therapeutically active compounds, already used successfully in the treatment of acute promyelocytic leukemia and other diseases (1 , 8, 9, 10) .

We observed that bile acids cooperated with low and physiological concentrations of ATRA and Vit D3 that are not effective on HL60 cell proliferation and differentiation. We also show that bile acids, as well as ATRA and Vit D3, caused a down-regulation of the Mbn gene encoding a serine protease directly involved in normal myelopoiesis (11) . Because bile acids such as chenodeoxycholic and ursodeoxycholic acid are already used successfully in the treatment of gallstones and cholestatic liver diseases with minor side effects, the results reported herein may have important clinical applications. Also, derivatives of bile acids might be designed with higher efficiency and lower cytotoxicity.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture.
HL60 human acute promyelocytic leukemia cells and THP-1 human monocytic leukemia cells were obtained originally from Dr. T. Breitman (National Cancer Institute, Bethesda, MD). HL60 and THP-1 cells were routinely passaged every 3 or 4 days in RPMI 1640 (Life Technologies, Inc., Paisley, United Kingdom) supplemented, respectively, with 10 and 5% FCS (Boehringer, Mannheim, Germany), 2 mM glutamine, penicillin (100 IU/ml), and streptomycin (100 IU/ml), all from Flow (Irvine, United Kingdom). Cells between passages 35 and 60 were used for all experiments described herein. For testing, the effects of bile acids or other drugs, aliquots of 2–3 x 105 cells taken at days 3 or 4 after passage, were suspended in the standard culture medium. Incubation was performed at 37°C in a humidified atmosphere, with 5% CO2 in air.

Drugs and Treatments.
PMA and the bile acids DCA, CDCA, and LCA were from Sigma Chemical Co. (La Verpillère, France). ATRA and Vit D3 were kind gifts from Hoffmann-LaRoche (Basel, Switzerland). The PKC inhibitors H-7 and staurosporine were from Calbiochem (La Jolla, CA).

LCA, PMA, and ATRA were first dissolved in DMSO; Vit D3 stock solution was in absolute ethanol, and all other drugs were dissolved in sterile 0.9% saline solution. All stock solutions were kept at -70°C, further diluted in RPMI just before use, and routinely added to cell suspensions under subdued light. Final concentrations of DMSO and ethanol did not exceed 0.1 or 0.01%, respectively, and these vehicle solvents had no effect on any of the parameters studied. Thus, one pooled control value is given in all tables and figures.

Cell Proliferation and Differentiation.
Drugs were added to 25-cm2 Falcon flasks (Oxnard, CA) containing 10 ml of HL60 or THP-1 cell suspensions. When tested in combination, drugs were added simultaneously, whereas bile acids were always added 15–30 min before retinoic acid or Vit D3. PKC inhibitors were added once (day 0) or repeatedly, as indicated. Leukemic cells were incubated for various periods of time, usually for 3 or 5 days. At the end of incubation, cell viability was determined by the trypan blue dye exclusion method. Aliquots containing about 106 HL60 cells were then taken for morphological examination, and their distribution in different stages of maturation and differentiation, and for the NBT and NSE tests for cell differentiation, as described previously (5) .

Cell Cycle Cytometry.
The distribution of HL60 cells among the G0-G1, S, and G2 + M phases of the cell cycle was estimated by fluorescence activated cell sorter, following DNA binding with propidium iodide, as described previously (5) .

RNA Isolation and Northern Blot Analysis of Mbn Gene Expression.
Total RNA was isolated according to the procedure of Chirgwin et al. (12) . RNA blots were obtained after electrophoretic separation in denaturing formaldehyde/agarose gels and transfer onto nylon membranes. RNA bands were visualized by autoradiography, following hybridization with 32P-labeled probes. A random priming Mbn cDNA probe corresponding to positions 260–630 of the Mbn sequence was described previously (11) . An even loading of cellular RNA on the gels was ascertained by 28S RNA controls, with ethidium bromide staining.

Statistical Analysis.
Student’s t test, ANOVA, and the Mann-Whitney nonparametric ranking test (one-tailed) and linear regression were performed where appropriate (13) .


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Effect of Combination between DCA and ATRA or Vit D3 on HL60 Cell Proliferation and Differentiation.
We studied the effect of DCA, ATRA, and Vit D3, each drug alone and in combination. We used DCA at four concentrations: 50 µM, which alone did not affect significantly cell proliferation and differentiation; 75 µM, which was only slightly effective; 100 µM, an effective and subtoxic concentration; and 150 µM, an effective but toxic one. ATRA and Vit D3 were used in a low concentration of 1 nM, which alone had no effect, and a high concentration of 10 nM, which when administered alone caused significant inhibition of cell proliferation and induced differentiation. Results presented in Table 1Citation show that all combination treatments with 100 µM DCA plus ATRA or Vit D3 were by far superior to the single treatments in the induction of HL60 cell differentiation. In general, the inhibition of cell proliferation paralleled this effect. The combination of 50 µM DCA, alone having no effect on cellular differentiation, showing only 5% NBT-positive cells, with ATRA at 1 and 10 nM, resulted in 22 and 80% NBT-positive cells, respectively. This low concentration of DCA, when used in combination with 10 nM Vit D3, gave 91% NBT-positive and 59% NSE-positive cells, whereas Vit D3 alone showed only 50 and 13% positive cells, respectively (data not shown). Also, the combination of 75 µM DCA (which alone had no effect, showing 6% NBT-positive cells), together with the noneffective concentration of 1 nM ATRA, or 1 nM Vit D3, resulted in 90 and 70% NBT-positive cells, respectively, reflecting a high degree of cell maturation and differentiation (data not shown).


View this table:
[in this window]
[in a new window]
  		Table 1 Effect of DCA, ATRA, and Vit D3 and their combinations on the proliferation and differentiation of HL60 cells

Results of four experiments, each run in duplicate, are shown. A total of 400 cells were analyzed for each treatment in the NBT and NSE test.

 
Treatment with DCA at 150 µM (alone giving 63% NBT-positive cells), in combination with 1 nM ATRA, increased the number of NBT-positive cells to 91%. Because this concentration of DCA was toxic, it was not used further. In contrast, 75 µM DCA was never toxic when used as a single drug or in any combination treatment. This concentration was therefore chosen for additional experiments on cell morphology and cell cycle.

Combination of CDCA with ATRA or Vit D3.
We showed that CDCA inhibited HL60 cell proliferation and induced differentiation (5) , and because it is used clinically in the treatment of gallstones and in cholestatic liver diseases with only minor side effects, we tested its effect in combination with either ATRA or Vit D3.

Results presented in Table 2Citation show that the combination of 60 µM CDCA (a treatment that alone had no effect), together with either ATRA or Vit D3, significantly enhanced cellular differentiation (NBT test), and that low concentrations of ATRA and Vit D3 could be used to obtain such results. In general, the inhibition of cell proliferation correlated well with the differentiation-inducing effect of the drug combinations used. Cell viability was >95% in all of these treatments, showing that none of them was cytotoxic. An isobologram presentation (4) of data, shown here together with our unpublished results on the induction of HL60 cell differentiation (NBT test) by bile acids, alone and in combination with Vit D3, showed that these interactions were additive (Fig. 1)Citation .


View this table:
[in this window]
[in a new window]
  		Table 2 Effect of CDCA, ATRA, Vit D3, and their combinations on the proliferation and differentiation of HL60 cells

Results of four experiments, each run in duplicate, are shown.

 


View larger version (12K):
[in this window]
[in a new window]
  		Fig. 1. An isobologram presentation of the effect of the combination of DCA or CDCA with Vit D3 on HL60 cell differentiation. An iso-effect of 75 ± 5% NBT-positive cells for DCA plus Vit D3 (•) and 50 ± 5% for CDCA plus Vit D3 ({circ}) is described by a straight line, pointing to an additive effect of these drug combinations. For further details see Berebaum (4).

 
Combination of DCA with PMA.
PMA was shown previously to induce the differentiation of HL60 cells toward macrophages (14) . Both PMA and bile acids were shown to affect PKC activity (15, 16, 17) and to act as tumor promoters (18 , 19) . We have, therefore, tested the effect of their combinations in HL60 cells.

Treatment of HL60 cells with 0.01 or 0.1 nM PMA had no significant effect on the number of NBT-positive cells (0- 1%), whereas DCA (50 µM) alone induced only 20% NBT-positive cells. In contrast, the combinations between DCA and these two PMA concentrations increased the number of NBT-positive cells to 35 and 75%, respectively, and enhanced the antiproliferative effect. Thus, results obtained for 0.1 nM PMA plus DCA were almost as pronounced as those obtained by 1 nM PMA alone, corresponding to 84% NBT-positive cells. On the basis of these results and further combinations studied, we concluded that PMA and DCA acted at best in an additive manner, perhaps because both drugs act on PKC or another common target.

Effect of Combination of Bile Acids DCA and CDCA with ATRA or Vit D3 on the Morphological Maturation and Differentiation of HL60 Cells.
To substantiate the beneficial effect of the combinations of bile acids with ATRA and Vit D3 on HL60 cellular differentiation that was apparent in the NBT test (Tables 1Citation 2)Citation or NSE test (Table 1)Citation , we have examined the Wright-Giemsa-stained cytospin slides for the classification of cells in different maturation stages according to: (a) cell size, cytoplasmic/nuclear area ratio; (b) presence of typical cytoplasmic granules (their size and coloration); and (c) presence of cytoplasmic vacuoles and pseudopod-like projections and nuclear shape (round, bar, kidney-like, segmented). Results presented in Table 3Citation showed that nontreated HL60 cells, as well as cells treated for 5 days with low concentrations of DCA (75 µM), ATRA (2 nM), or Vit D3 (1 nM), did not respond in the NBT test and did not show morphological maturation. A slight effect on maturation and NBT oxidative burst was obtained with 2 nM Vit D3. However, the combination of 75 µM DCA with 1 nM Vit D3 markedly increased 3-fold the number of cells in intermediate stages of maturation, and this effect was further increased when 2 nM Vit D3 was applied together with DCA. In this case, there were also 25% of cells in the more mature and well-differentiated stage of monocytes/macrophages (Table 3Citation and Fig. 2Citation ). The combination of 75 µM DCA with 2 nM ATRA resulted also in the progression of HL60 cells along the maturation pathway, with the appearance of 87% of mature cells, which appeared to be a mixed population of monocytes and granulocytes (20) . This combination treatment resulted in 95% of NBT-positive cells. In all of the treatments, there was a very close correlation between the morphological appearance of more mature, differentiated cells and the NBT test. The combination of 60 µM CDCA (alone being without effect), together with 5 nM Vit D3 that alone increased only slightly the number of cells in intermediate stages of maturation and did not induce morphological differentiation (see Table 2Citation ), resulted in the appearance of a high percentage of intermediate-stage cells and a significant number of mature monocytes/macrophages (data not shown). We therefore concluded that the NBT test was highly reliable, because it correlated well with our morphological-cytological data.


View this table:
[in this window]
[in a new window]
  		Table 3 Effect of DCA, Vit D3, ATRA, and their combinations on the morphological maturation of HL60 cells

 


View larger version (142K):
[in this window]
[in a new window]
  		Fig. 2. The effect of combination of DCA with ATRA or Vit D3 on the morphological maturation-differentiation of HL60 cells. A, nontreated control. B, HL60 cells treated with 75 µM DCA plus 1 nM ATRA. C, 75 µM DCA plus 1 nM Vit D3; arrow, apoptotic nucleus. D, 100 µM DCA plus 2 nM ATRA. Note the mixed cell population, monocytic (m) plus granulocytic-like cells (g). All treatments were for 5 days. Note the appearance of mature cells in all of the drug combinations used. The morphology of HL60 cells treated with the above-mentioned drugs and concentrations in a single treatment (except for 100 µM DCA) was not significantly different from control (not shown). Bar, 20 µM (same magnification in A–D).

 
To further ascertain the validity of NBT test in our studies, we have tested for a possible direct effect of bile acids on the PMA-induced oxidative burst. We have preincubated HL60 cells that were induced for maturation-differentiation by 5 days treatment with various concentrations of ATRA or Vit D3, for 30 min with bile acids (DCA, CDCA and LCA) in the concentrations used in our studies and two times higher. We found that bile acids had no effect on the NBT test under these conditions (three separate experiments).

Effect of Combinations between DCA, ATRA, and Vit D3 on the Cell Cycle.
When bile acids were administered in effective concentrations causing differentiation in HL60 cells, a significant G0-G1 cell cycle arrest occurred (5) . Here, we tested the effect of combinations of DCA and ATRA or Vit D3 at concentrations that alone caused only slight effect on cellular differentiation and the cell cycle. This bile acid was used in a concentration of 75 µM, which had no effect by itself, and in an effective concentration of 100 µM. After 5 days of treatment with 75 µM DCA combined with 2 nM of ATRA, there was a significant accumulation of cells at G0-G1 phase, from 50 to 76% (Fig. 3)Citation . When DCA was added in a dose that alone resulted in the accumulation of 76% of cells at G0-G1, its effect was enhanced by the combination with 2 nM Vit D3, reaching a value of 85% of cells in G0-G1 (data not shown). Also, the combination between 100 µM DCA with either ATRA or Vit D3 accelerated the accumulation of cells at G0-G1, which was already 73 and 76% at 3 days, as compared with 62% obtained with DCA alone (data not shown).



View larger version (19K):
[in this window]
[in a new window]
  		Fig. 3. Distribution of HL60 cells in the different phases of the cell cycle after 5 days culture in presence of 75 µ DCA, 2 nM ATRA, and their combinations. SE were ±2–3% for all determinations. Means of two experiments run in duplicate are shown.

 
Effect of Combinations between Bile Acids and ATRA on the Differentiation of THP-1 Human Leukemia Cells.
As shown in Fig. 4Citation , treatment of THP-1 human monocytic leukemia cells with combinations of DCA or CDCA with ATRA was also beneficial in inducing monocytic differentiation. These cells are known to respond only to very high doses of ATRA (21) . However, when combined with bile acids, the dose of ATRA can be considerably lowered (~10-fold).



View larger version (58K):
[in this window]
[in a new window]
  		Fig. 4. The effect of bile acids, ATRA, and their combinations on the differentiation of THP-1 Cells. All treatments were for 5 days. *, significantly different (P < 0.05) from the corresponding single treatment. Combinations of 10 µM ATRA with bile acids were toxic (not shown). Bars, SE.

 
Effect of PKC Inhibitors on Cell Differentiation Induced by Bile Acids.
We have shown previously that the PKC inhibitor sphinganine inhibited the differentiation induced by the bile acids in HL60 cells (5) , thus implying an important role of PKC as a mediator in this process. This is in agreement with previous reports obtained with purified rat brain PKC, in rat and human colon, and cell lines treated with bile acids (15, 16, 17) . Here, we have tested another PKC inhibitor, H-7, at 10 and 20 µM (22) . Results presented in Fig. 5Citation show that 20 µM H-7 inhibited significantly the cell differentiation induced by the three bile acids. A reduced inhibition level was obtained with 10 µM H-7 (data not shown). Interestingly, the inhibition of HL60 cell proliferation by bile acids was not much attenuated by H-7. When administered alone, 10 or 20 µM H7 had no effect on cellular differentiation and inhibited cell proliferation by 34% only at the higher concentration of 20 µM (data not shown).



View larger version (71K):
[in this window]
[in a new window]
  		Fig. 5. The effect of H-7 (20 µM) and staurosporine (5 nM) on the differentiation-inducing effects of DCA (100 µM), CDCA (75 µM), and LCA (60 µM) in HL60 cells. Cellular differentiation was expressed as a percentage of NBT-positive cells. *, treatments were statistically different from the corresponding single treatments (P < 0.05). Bars, SE.

 
Because staurosporine is a very potent protein kinase inhibitor that enhances or induces differentiation in various cell types (23 , 24) , we tested this drug in combination with bile acids. At 5 nM, staurosporine alone did not significantly affect HL60 cell proliferation and differentiation. However, when combined with bile acids, it strongly enhanced cellular differentiation (Fig. 5)Citation . The potentiation of the effect of bile acids by 5 nM staurosporine was also associated with a markedly enhanced antiproliferative effect and only slight cytotoxicity. At a higher concentration of 20 nM, staurosporine alone induced considerable cell differentiation (61% NBT-positive HL60 cells), and when combined with bile acids it enhanced further their effect. However, these treatments were cytotoxic, resulting in 60–75% cell viability (data not shown).

Morphological examination of maturation and differentiation of HL60 cells treated with H-7 or staurosporine, alone and in combination with bile acids, agreed with results obtained in NBT test. Also, there was an additive effect of these drug combinations on the morphological appearance of apoptotic cells, which increased respectively from 3 to 8% with 5 nM staurosporine and bile acids alone to 14–18% in the combination treatments.

Effect of Bile Acids and Their Combination with ATRA or Vit D3 on Mbn Gene Expression.
The Mbn gene encodes a serine protease (leukocyte proteinase 3) and is specifically expressed in human promyelocytic hematopoietic cells (25) . It is down-regulated during both normal myelopoiesis and the differentiation of human promyelocytic cell lines, including HL60 cells treated with different inducers, such as ATRA, Vit D3, and PMA (11) . Inhibition of Mbn expression by specific antisense oligodeoxynucleotide was shown to cause monocytic differentiation of HL60 cells (11) . We were, therefore, interested to test the effect of bile acids on the expression of Mbn transcripts in HL60 cells. We first examined the effect of CDCA (75 µM) and LCA (60 µM) in concentrations that were shown to maximally induce differentiation in HL60 cells (5) . These conditions were compared with 0.5 µM ATRA and 50 nM Vit D3.

Results presented in Fig. 6ACitation show that Mbn mRNA levels (1.3 kb) were remarkably decreased in cells treated for 5 days with the bile acids LCA (95% decrease) and CDCA (90%), and a similar effect was observed with the differentiation-inducing agents ATRA or Vit D3 (95%), in agreement with previous results (11) . Densitometric analysis of the Mbn transcripts normalized with the 28S RNA bands showed that addition of 0.1 and 1 µM ATRA decreased the expression of Mbn by 15–25% at day 2 and 25–80% at day 4, respectively (data not shown). In comparison, a time course study with LCA (60 µM) in Fig. 6BCitation showed that this bile acid down-regulated Mbn transcripts slightly at day 1 (10% decrease) but very significantly at day 2 (40%). This effect was still evident and persistent at day 5 (65%). In addition, this down-regulation of the Mbn message by LCA at day 2 preceded the effect of this bile acid on the NBT test, which occurred only at days 3–4 (5) . This is significant, because we observed that the NBT reaction (oxidative burst) is typically preceding the cell cycle arrest and the morphological changes that accompany HL60 cell maturation and differentiation (5 , 26) .



View larger version (36K):
[in this window]
[in a new window]
  		Fig. 6. The effect of bile acids, ATRA, and Vit D3, on Mbn mRNA expression in HL60 cells by Northern blot. A, cells treated with single drugs for 5 days. Lanes (from left): nontreated controls; 0.5 µM ATRA; 60 µM LCA; 50 nM Vit D3; and 75 µM CDCA. Note the significant down-regulation of Mbn transcripts in all of the treatments, as compared with very high expression in control HL60 cells. B, time course of the effect of LCA (60 µM) on Mbn mRNA expression level in HL60 cells measured 1, 2, and 5 days after treatment. Note the significant Mbn down-regulation evident at day 2, which persisted for 5 days. C, the effect of combination of 50 µM CDCA with 2 nM ATRA or with 5 nM Vit D3. Treatments were for 4 days. Note the down-regulation of Mbn message after treatment with CDCA plus Vit D3.

 
We then studied the effect of a combination of a low concentration of CDCA (50 µM, which alone did not induce differentiation in HL60 cells), together with low doses of ATRA (2 nM) or Vit D3 (5 nM). Fig. 6CCitation shows that the combination of CDCA with Vit D3 caused additional down-regulation in Mbn mRNA (90%), as compared with the change observed by either of these drugs: 65% with CDCA or 45% with Vit D3. In contrast, addition of 2 nM ATRA, inducing 31% decrease in Mbn transcript, with 50 µM CDCA (65% decrease) were not additive (35% decrease).

As mentioned above, down-regulation of the Mbn gene precedes the differentiation of HL60 cells triggered by different inducers and is not related to the "decision" to follow the monocytic or the granulocytic pathways of maturation-differentiation (11) . The fact that bile acids alone, or in combination with another effective inducer, can down-regulate Mbn is interesting; and the specific combination of CDCA plus Vit D3 may be of special relevance because both drugs are already used clinically (although for different objectives). The combination of CDCA with ATRA was not additive in terms of Mbn mRNA expression (Fig. 6C)Citation , in spite of the beneficial effect of this combination in inducing HL60 cell differentiation (shown by NBT test and morphological examination). However, posttranscriptional and/or posttranslational effects are certainly possible.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we have demonstrated that bile acids, compounds that were shown previously by us to induce differentiation of HL60 cells in vitro (5) , cooperate with ATRA or Vit D3 to induce a more pronounced differentiation phenotype in human leukemic cells HL60 and THP-1. The concentrations of these two morphogens could be lowered about 5–10 times, to levels that by themselves had no effect or were only slightly effective. Because ATRA and Vit D3 exert side effects when used clinically, lowering their concentration without loosing therapeutic gain is important. These drug combinations induced mainly monocytic cell differentiation. However, it appeared that under certain drug combinations, a mixed population of two lineages could emerge, similar to previous findings (20) . In our studies (5) and herein, we have shown that both primary (CDCA) and secondary (DCA and LCA) hydrophobic bile acids can inhibit HL60 cell proliferation and induce maturation and differentiation. Cholic acid and ursodeoxycholic (50 to 200 µM), which are water soluble, did not have such effects and even stimulated cell proliferation (data not shown). Indeed, bile acids can also enhance cellular proliferation, in vitro and in vivo, independent of cytotoxicity (27) . In HT-29 human colonic cancer cells, this effect was confined to narrow concentration "windows," which differed for the different bile acids (28) , similar to the situation we described.

The cooperative effect of bile acids with Vit D3 or ATRA may be explained as follows. Bile acids were shown previously to affect PKC activity (15, 16, 17) , to enhance the phosphorylation of selected PKC substrates (15) , and to exert a differential effect on PKC isoforms (29) . Recently, deoxycholate was found to increase the expression of c-fos mRNA and fos/jun binding to AP1 sites in HT-29 human colon cancer cells (30) . Also, Hirano et al. (31) have shown that CDCA specifically induced AP1 binding activity in nuclear extracts of human colon carcinoma Lovo cells.

Our results obtained here with H-7 revealed that PKC is an important mediator of the effect of bile acids on HL60 cellular differentiation. In agreement, PKC isoenzymes (32, 33, 34) and AP1 response elements (35 , 36) were strongly implicated in the regulation of proliferation and monocytes/macrophage differentiation of human leukemic cells. The divergent effects of the PKC inhibitors H-7 and staurosporine on differentiation might be explained by their differential activity on the PKC isoenzymes. In addition, not all cellular targets of staurosporine are known yet, and variable effects of this drug on cell cycle arrest and apoptosis were described recently (37, 38, 39, 40, 41) . Staurosporine administered at 10–200 nM was shown to induce apoptotic bodies, without concomitant DNA fragmentation in MOLT-4 cells (40) . In HL60 cells, it caused DNA fragmentation only at concentrations 10–40 times higher than those used herein (41) . In our experiments, the combination of staurosporine with bile acids (DCA and LCA) increased the number of morphologically apoptotic HL60 cells in an additive manner. It might be useful, therefore, to explore further the mechanism related to positive interactions between bile acids and staurosporine implicated from our data.

Another important observation reported herein is the down-regulation of the Mbn gene induced by bile acids in HL60 cells. Mbn is a neutral serine proteinase, identical to proteinase 3 (25) . Mbn gene expression is confined to the promyelocytic stage of polymorphonuclear leukocyte maturation and is switched off upon myeloid differentiation. Little is known about its biological targets. However, Mbn was recently shown to hydrolyze specifically the Mr 28,000 heat shock protein hsp 28 involved in cellular growth and differentiation (42) . Mbn is a common target to a variety of inducers of promyelocytic cellular differentiation, independent of the choice between monocytic versus granulocytic pathways (11 , 43) .

Our data therefore strongly suggest that the Mbn promoter is a possible target of bile acids or transcription factors under the control of signaling pathways activated by bile acids and PKC-dependent mechanisms. In favor of this hypothesis is the recently described mechanism for the control of liver cholesterol 7{alpha}-hydroxylase gene (CYP7{alpha}). This gene is regulated by a negative feedback of hydrophobic bile acids reaching the liver by enterohepatic circulation and also by cholesterol and by steroid and thyroid hormones. BARE-I and BARE-II were identified in the CYP7{alpha} promoter using DNase I footprinting, electrophoretic mobility shift assay and transient transfection of HepG2 cells with a promoter/luciferase reporter gene (44 , 45) . BARE-I was shown to contain a direct repeat of hormone response elements separated by four nucleotides (DR4). Chicken ovalbumin upstream promoter transcription factor (COUP-TFII) binds this DR4 and transactivates the CYP7{alpha} gene. DR4 also binds the liver x receptor/RXR complex mediating oxysterol-dependent transactivation (44 , 45) . BARE-II is the major BARE element involved in the transcriptional repression of CYP7{alpha} by hydrophobic bile acids. It also contains three HRE-like sequences that form two overlapping nuclear receptor binding sites. One is a direct repeat separated by one nucleotide DR1 (-146-TGGACTtAGTTCA-134), and the other is a direct repeat separated by five nucleotides DR5 (-139-AGTTCA aggcc GGGTAA-123). The DR5 binds the RXR/retinoic acid receptor heterodimer.

BARE-I and BARE-II are highly conserved in different mammalian species and share a novel sequence, AGTTCAAG. Most interestingly, the Mbn promoter (46 , 47) also harbor a BARE-II like sequence (AGTTCCAG) between nucleotides -156/-143 and several components of the transcription machinery identified in the CYP7{alpha} promoter, including Vit D3 and thyroid hormone response elements, and particularly, the RXR/retinoic acid receptor motif overlapping BARE-II. Very recent data identified a bile acid signaling pathway leading to the activation of the orphan nuclear receptor farnesoid X receptor, thereby regulating the expression of CYP7{alpha} and the intestinal bile acid binding protein I-BABP (48, 49, 50) . The I-BABP promoter is activated by the farnesoid X receptor and bile acids and contains the inverted repeat response element (IR-1; Ref. 49 ) that functions as a palindromic BARE (AGGTGAATAACCT). More details of these molecular interactions are needed to clarify the role of the BARE-like sequence in the Mbn promoter using reporter gene assays and electrophoretic mobility shift assay. Posttranscriptional modulations might also occur (25) . All of these possibilities need further investigation.

Until recently, bile acids were considered in the context of human cancer mostly as harmful tumor-promoting agents. However, a closer examination of their physiological roles and biochemical relationships to cholesterol and its steroid hormones and Vit D3 metabolites, and considering the convergence in their interactions with nuclear proteins/receptors and genomic response elements, bile acids make attractive candidates for useful purposes. Some bile acids are already used in therapeutics (51 , 52) . Their chemical modifications might also improve their benefits in the future (53) . Taken together, our data suggest that bile acids and their derivatives may exert a therapeutic effect in human leukemic cells. These compounds may also have important functions in normal development and in the neoplastic progression of the gastrointestinal mucosa.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by INSERM and a grant from La Ligue Nationale Contre le Cancer. Back

2 To whom requests for reprints should be addressed, at The Hebrew University of Jerusalem, Faculty of Agriculture, Department of Animal Sciences, Post Office Box 12, Rehovot 76100, Israel. Phone: 972-8-9489304; Fax: 972-8-9465763. Back

3 The abbreviations used are: NBT, nitro blue tetrazolium; ATRA, all-trans retinoic acid; Vit D3, 1,25-dihydroxyvitamin D3; Mbn, myeloblastin; PMA, phorbol myristate acetate; DCA, sodium deoxycholate; CDCA, sodium chenodeoxycholate; LCA, lithocholic acid; PKC, protein kinase C; H-7, 1,5-isoquinolinesulfonyl-2-methyl-piperazine; NSE, nonspecific esterase; BARE, bile acid response element; RXR, retinoid X receptor. Back

Received 6/29/99. Accepted 12/ 2/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Paquette R. L., Koeffler H. P. Differentiation therapy. Hematol. Oncol. Clin. N. Am., 6: 687-706, 1992.[Medline]
  2. Scott R. E. The differentiation therapy of cancer: past, present, and future. Mol. Cell Differ., 3: 157-173, 1995.
  3. Chou T. C., Talalay P. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.[Medline]
  4. Berenbaum M. C. Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res., 35: 269-335, 1981.[Medline]
  5. Zimber A., Chedeville A., Gespach C., Abita J. P. Inhibition of proliferation and induction of monocytic differentiation in HL60 human promyelocytic leukemia cells treated with bile acids in vitro. Int. J. Cancer, 59: 71-77, 1994.[Medline]
  6. Heikkinen J., Maentausta O., Yostalo P., Janne O. Serum bile acid levels in intrahepatic cholestasis of pregnancy during treatment with phenobarbital and cholestyramine. Eur. J. Obstet. Reprod. Biol., 14: 153-162, 1982.
  7. Kwekkeboom J., Princen H. M. G., Van Voorthuizen E. M., Meijer P., Kempen J. M. Comparison of taurocholate accumulation in cultured hepatocytes of pig, rat, and man. Biochem. Biophys. Res. Commun., 162: 619-625, 1989.[Medline]
  8. Degos L., Dombert H., Chomiene C., Daniel M. T., Miclea J. M., Chastang C., Castaigne S., Fennaux P. All-trans retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood, 85: 2643-2653, 1995.[Free Full Text]
  9. Borden E. C., Lotan R., Levens D., Young C. W. Differentiation therapy of cancer: laboratory and clinical investigations. Cancer Res., 53: 4109-4115, 1993.[Free Full Text]
  10. Hellstrom E., Robert K. H., Soppi E., Ost A., Putkonen P. O., Gahrton G. Effects of retinoic acid, 1,25- dihydroxyvitamin D3, 1-ß-D-arabinofuranosylcytosine and {alpha}-interferon on bone marrow cells from patients with myelodysplastic syndromes. Leuk. Res., 13: 1113-1121, 1989.[Medline]
  11. Bories D., Raynal M. C., Solomon D. H., Darzynkiewicz Z., Cayre Y. E. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell, 59: 959-968, 1989.[Medline]
  12. Chirgwin J. J., Przbyla A. E., MacDonald R. J., Rutter W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 249-260, 1979.
  13. Snedecor G. W., Cochran W. G. Statistical Methods120-134, Iowa State University Press Ames, IA 1967.
  14. Rovera G., Santoly D., Damsky C. Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with phorbol diester. Proc. Natl. Acad. Sci. USA, 76: 2779-2783, 1979.[Abstract/Free Full Text]
  15. Huang X. P., Fan X. T., Desjeux J. F., Castagna M. Bile acids, non-phorbol-ester-type tumor promoters, stimulate the phosphorylation of protein-kinase-C substrates in human platelets and colon cell line HT29. Int. J. Cancer, 52: 444-450, 1992.[Medline]
  16. Craven P. A., Pfanstiel J., DeRubertis F. R. Role of reactive oxygen in bile salt stimulation of colonic epithelial proliferation. J. Clin. Investig., 77: 850-859, 1987.
  17. Fitzer C. J., O’Brian C. A., Gullieim J. G., Weinstein I. B. The regulation of protein kinase C by chenodeoxycholate, deoxycholate and several structurally related bile acids. Carcinogenesis (Lond.), 8: 217-220, 1987.[Abstract/Free Full Text]
  18. Diamond L., O’Brien T. G., Baird W. M. Tumor promoters and the mechanism of tumor promotion. Adv. Cancer Res., 32: 1-74, 1980.[Medline]
  19. Reddy N. S., Wynder E. L. Metabolic epidemiology of colon cancer: fecal bile acids and neutral steroids in colon-cancer patients with adenomatous polyps. Cancer (Phila.), 39: 2533-2539, 1977.[Medline]
  20. Masciculli R., Testa U., Barberi T., Samoggia P., Tritarelli E., Pustorino R., Mastroberardino G., Camagna A., Pestorino R., Mastroberardino G., Camagna A., Peschle C. Combined vitamin D3/retinoic acid induction of human promyelocytic cell lines: enhanced phagocytic cell maturation and hybrid granulomonocytic phenotype. Cell Growth Differ., 6: 493-503, 1995.[Abstract]
  21. Tsuchiya S., Kobayashi Y., Goto Y., Okumura H., Nakae S., Konno T., Tada K. Induction of maturation in cultured human monocytic leukemia cells by a phorbol diester. Cancer Res., 42: 1530-1536, 1982.[Abstract/Free Full Text]
  22. Hidaka H., Inagaki M., Kawamoto S., Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry, 23: 5036-5041, 1984.[Medline]
  23. Okazaki T., Kato Y., Mochizuki T., Tashima M., Sawada H., Uchino H. Staurosporine, a novel PKC inhibitor, enhances HL-60 cell differentiation induced by several compounds. Exp. Hematol., 16: 42-48, 1988.[Medline]
  24. Stanwell C., Dlugosz A. A., Yuspa S. H. Staurosporine induces a complete program of terminal differentiation in neoplastic mouse keratinocytes via activation of protein kinase C. Carcinogenesis (Lond.), 17: 1259-1265, 1996.[Abstract/Free Full Text]
  25. Chen T., Meier R., Ziemiecki A., Fey M. F., Tobler A. Myeloblastin/proteinase 3 belongs to the set of negatively regulated primary response genes expressed during in vitro myeloid differentiation. Biochem. Biophys. Res. Commun., 200: 1130-1135, 1994.[Medline]
  26. Bollag, W., and Peck, R. Modulation of growth and differentiation by combined retinoids and cytokines in cancer. In: W. K. Hong and R. Lotan (eds.), Retinoids in Oncology, pp. 89–108, New York: Marcel Dekker, 1993.
  27. Barone M., Francavilla A., Polimeno L., Ierardi E., Romanelli D., Berloco P., di Leo A., Panella C. Modulation of rat hepatocyte proliferation by bile salts: in vitro and in vivo studies. Hepatology, 23: 1159-1166, 1996.[Medline]
  28. Pandak W. M., Stravitz R. T., Lucas V., Heuman D. M., Chiang J. Y. L. Hep G2 cells: a model for studies on regulation of human cholesterol 7{alpha}-hydroxylase at the molecular level. Am. J. Physiol., 270: G401-G410, 1996.[Abstract/Free Full Text]
  29. Beuers U., Trockmorton D. C., Anderson M. S., Isales C. M., Thasler W., Kullak-Ublick G. A., Sauter G., Koebe H. G., Paumgartner G., Boyer J. L. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes. Gastroenterology, 110: 1553-1563, 1996.[Medline]
  30. Matheson H., Branting C., Rafter I., Okret S., Rafter J. Increased c-fos mRNA and binding to the AP-1 recognition sequence accompanies the proliferative response to deoxycholate of HT29 cells. Carcinogenesis (Lond.), 17: 421-426, 1996.[Abstract/Free Full Text]
  31. Hirano F., Tanaka H., Makino Y., Okamoto K., Hiramoto M., Handa H., Makino I. Induction of the transcription factor AP-1 in cultured human colon adenocarcinoma cells following exposure to bile acids. Carcinogenesis (Lond.), 17: 427-433, 1996.[Abstract/Free Full Text]
  32. Mischak H., Pierce J., Goodnight J., Kazanietz M., Blumberg P., Muschinski F. Phorbol-ester-induced myeloid differentiation is mediated by protein kinase C-{alpha} and {delta} and not by protein kinase C-ßII, -{epsilon}, -{zeta}, and - {eta}. J. Biol. Chem., 268: 20110-20115, 1993.[Abstract/Free Full Text]
  33. Seibenhener M., Wooten M. Heterogeneity of protein-kinase-C isoform expression in chemically induced HL60 cells. Exp. Cell Res., 207: 183-188, 1993.[Medline]
  34. Yung B. Y. M., Hui E. K. W. Differential regulation of protein kinase C isoenzymes during sphinganine potentiation of retinoic acid-induced granulocytic differentiation in human leukemia HL-60 cells. Biochem. Biophys. Res. Commun., 196: 1390-1400, 1993.[Medline]
  35. Mollinedo F., Gajate C., Tugores A., Flores I., Naranjo J. R. Differences in expression of transcription factor AP-1 in human promyelocytic HL-60 cells during differentiation towards macrophages versus granulocytes. Biochem. J., 294: 137-144, 1993.
  36. Gaynor R., Simon K., Koeffller P. Expression of c-jun during macrophage differentiation of HL-60 cells. Blood, 77: 2618-2623, 1991.[Abstract/Free Full Text]
  37. Gadbois D. M., Hamaguchi J. R., Swank R. A., Bradbury E. M. Staurosporine is a potent inhibitor of P34 cdc2 and P34 cdc2-like kinases. Biochem. Biophys. Res. Commun., 184: 80-85, 1992.[Medline]
  38. Nishi K., Schnier J. B., Bradbury E. M. The accumulation of cyclin-dependent kinase inhibitor p27Kip1 is a primary response to staurosporine and independent of G1 cell cycle arrest. Exp. Cell Res., 243: 222-231, 1998.[Medline]
  39. Traganos F., Gong J., Ardelt B., Darzynkiewicz Z. Effect of staurosporine on MOLT-4 cell progression through G2 and on cytokinesis. J. Cell Physiol., 158: 535-544, 1994.[Medline]
  40. Falcieri E., Martelli A. M., Bareggi R., Cataldi A., Cocco L. The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-4 cells without concomitant DNA fragmentation. Biochem. Biophys. Res. Commun., 193: 19-25, 1993.[Medline]
  41. Jarvis W. D., Turner A. J., Povirk L. F., Traylor R. S., Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res., 54: 1707-1714, 1994.[Abstract/Free Full Text]
  42. Spector N. L., Hardy L., Ryan C., Miller W. H., Humes J. L., Nadler L. M., Luedke E. 28-kDa mammalian heat shock protein, a novel substrate of a growth regulatory protease involved in differentiation of human leukemia cells. J. Biol. Chem., 270: 1003-1006, 1995.[Abstract/Free Full Text]
  43. Labbaye C., Zhang J., Casanova J. L., Lanotte M., Teng J., Miller W. H., Cayre Y. E. Regulation of myeloblastin messenger RNA expression in myeloid leukemia cells treated with all-trans retinoic acid. Blood, 81: 475-481, 1993.[Abstract/Free Full Text]
  44. Crestani M., Sadeghpour A., Stroup D., Galli G., Chiang J. Y. L. Transcriptional activation of the cholesterol 7 {alpha}-hydroxylase gene (CYP7A) by nuclear hormone receptors. Lipid Res., 39: 2192-2200, 1998.[Free Full Text]
  45. Foti P., Stroup D., Chiang J. Y. L. Basic transcription element binding protein (BTEB) transactivates the cholesterol 7 {alpha}-hydroxylase gene (CYP7A). Biochem. Biophys. Res. Comm., 253: 109-113, 1998.[Medline]
  46. Zimmer M., Medcalf R. L., Fink T. M., Mattman C., Lichter P., Jene D. E. Three human elastase-like genes coordinately expressed in the myelomonocyte lineage are organized as a single genetic locus on 19pter. Proc. Natl. Acad. Sci. USA, 89: 8215-8219, 1992.[Abstract/Free Full Text]
  47. Ballerini P., Besancon F., Cayre Y. E. Effect of translocation t(15;17) on the gene expression regulation of myeloblastin during all-trans retinoic acid induced myeloid differentiation in human leukemic cells. C. R. Soc. Biol. Fil., 189: 521-530, 1995.
  48. Wang H., Chen J., Hollister K., Sowers L. C., Forman B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell, 3: 543-554, 1999.[Medline]
  49. Makishima M., Okamoto A. Y., Repa J. J., Tu H., Leamed R. M., Luk A., Hull M. V., Lustig K. D., Mangelsdorf D. J., Bei S. Identification of a nuclear receptor for bile acids. Science (Washington DC), 284: 1362-1365, 1999.[Abstract/Free Full Text]
  50. Parks D. J., Blachard S. G., Bledoe R. K., Chandra G., Consler T. G., Kliewer S. A., Stimmel J. B., Willson T. M., Zavacki A. M., Moore D. D., Lehmann J. M. Bile acids: natural ligands for an orphan nuclear receptor. Science (Washington DC), 284: 1365-1368, 1999.[Abstract/Free Full Text]
  51. Poupon R. E., Balkau B., Eschwege E., Poupon R. A. A multicenter controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N. Engl. J. Med., 324: 1548-1554, 1991.[Abstract]
  52. Palma J., Reyes H., Ribalta J., Hermandez I., Sandoval L., Almuna R., Liepins J., Lira F., Sedano M., Silva O., Toha D., Silva J. J. Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo. J. Hepatol., 27: 1022-1028, 1997.[Medline]
  53. Kramer W., Wess G., Enhsen A., Bock K., Falk E., Hoffmann A., Neckermann G., Gantz D., Schulz S., Nickau L., Petzinger E., Turley S., Dietschy J. M. Bile acid derived HMG-CoA reductase inhibitors. Biochim. Biophys. Acta, 1227: 137-154, 1994.[Medline]



This article has been cited by other articles:


Home page
 Infect. Immun.Home page
A. M. McCord, S. I. Resto-Ruiz, and B. E. Anderson
Autocrine Role for Interleukin-8 in Bartonella henselae-Induced Angiogenesis
Infect. Immun., September 1, 2006; 74(9): 5185 - 5190.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
T. Oda, K. Hirota, K. Nishi, S. Takabuchi, S. Oda, H. Yamada, T. Arai, K. Fukuda, T. Kita, T. Adachi, et al.
Activation of hypoxia-inducible factor 1 during macrophage differentiation
Am J Physiol Cell Physiol, July 1, 2006; 291(1): C104 - C113.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
H Kazumori, S Ishihara, M A K Rumi, Y Kadowaki, and Y Kinoshita
Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium
Gut, January 1, 2006; 55(1): 16 - 25.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
R. Adachi, Y. Honma, H. Masuno, K. Kawana, I. Shimomura, S. Yamada, and M. Makishima
Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative
J. Lipid Res., January 1, 2005; 46(1): 46 - 57.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
A. Abe, H. K. Poucher, M. Hiraoka, and J. A. Shayman
Induction of lysosomal phospholipase A2 through the retinoid X receptor in THP-1 cells
J. Lipid Res., April 1, 2004; 45(4): 667 - 673.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
J. P. Seery
Stem cells of the oesophageal epithelium
J. Cell Sci., January 5, 2002; 115(9): 1783 - 1789.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
Y. M. van der Geld, P. C. Limburg, and C. G. M. Kallenberg
Proteinase 3, Wegener's autoantigen: from gene to antigen
J. Leukoc. Biol., February 1, 2001; 69(2): 177 - 190.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimber, A.
Right arrow Articles by Gespach, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimber, A.
Right arrow Articles by Gespach, C.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research